CervoMed
CRVO
13 hedge funds and large institutions have $924K invested in CervoMed in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
8% more funds holding
Funds holding: 12 → 13 (+1)
0.16% less ownership
Funds ownership: 6.13% → 5.97% (-0.16%)
8% less capital invested
Capital invested by funds: $1M → $924K (-$79.3K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$233 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$28.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.97K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$233 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $368K | +$233 | +28 | +0.1% |
|
|
2
Renaissance Technologies
New York
| $196K | -$28.9K | -3,466 | -12% |
|
3
BlackRock
New York
| $166K | – | – | – |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $87K | -$233 | -28 | -0.2% |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $84.5K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $14K | +$4.5K | +540 | +41% |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
8
Morgan Stanley
New York
| $2.77K | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| $1.63K | -$2.97K | -356 | -62% |
|
10
Wells Fargo
San Francisco,
California
| $637 | – | – | – |
|
|
TF
11
TimeScale Financial
Danvers,
Massachusetts
| $48 | – | – | – |
|
|
12
Bank of America
Charlotte,
North Carolina
| $20 | +$25 | +3 | New |
|
|
CCM
13
Connective Capital Management
Palo Alto,
California
| $5 | +$8 | +1 | New |
|
CRVO Hedge Fund Activity: Q4 2022 in Review
13 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in CervoMed (CRVO) for Q4 2022, worth a combined $924K — down 7.9% from $1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CRVO positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $4.5K. The largest seller was Renaissance Technologies, cutting an estimated $28.9K.
- 13 institutional investors held CervoMed (CRVO) as of Q4 2022, up from 12 in Q3 2022.
- Funds reported $924K of CervoMed stock for Q4 2022, down 7.9% quarter-over-quarter.
- 2 funds opened new CervoMed positions in Q4 2022 and 0 closed out, a net change of +2 holders.
- The largest CervoMed buyer in Q4 2022 was Tower Research Capital (TRC), an estimated $4.5K added.
- The largest CervoMed seller in Q4 2022 was Renaissance Technologies, an estimated $28.9K sold.
Based on aggregated 13F filings for Q4 2022.